Talk Cancer » Lung Cancer » Hydrazine sulfate use in fighting cancer

Hydrazine sulfate use in fighting cancer

Categories: Lung Cancer

Question:

– Hide quoted text — Show quoted text – Does anyone have any knowledge of, or even possibly, experience with, Hydrazine sulfate in the use of the regression of cancer? Studies were compiled by the Syracuse Cancer Research Institute/Dr. Joseph Gold on the effectiveness of Hydrazine sulfate in the successful reversal of weight loss and debilitation in some cancer patients. It was also discovered that Hydrazine sulfate regressed or stabilized tumors in some patients also.  The studies that I have read about so far have mentioned primarily brain and lung cancers as far as regression or stabilization of tumors. One of my questions is:  is this substance something that can be used in lymphomas (my mother has Non-Hodgkins lymphoma)?  She has not had any problems with weight loss so far; on the contrary, she is still overweight and is concerned that this substance, if used, would actually increase her weight – she is mainly looking at Hydrazine sulfate for the tumor regression/stabilization properties. Interferon was suggested to her for the same reasons, but she isn’t too crazy about the idea of this because of the possibly problematic side effects, and the constant trips to the doctor’s office to have it administered. My mother’s oncologist gave us a printout off of the internet about H.S. and tried to contact Dr. Gold by mail, but hasn’t had any luck so far.  I believe this is somewhat new to him, also.  We have tried to contact Dr. Gold by phone, but the receptionist stated that calls are not taken from patients, only medical personnel, so we are having a tough time getting any useful info on this.  Our doctor’s office keeps giving us other numbers, but they are just pharmacy supply places or won’t give out a lot of info over the phone (without $).  So far I haven’t been able to find anything specific to Hydrazine sulfate used with lymphoma on my internet searches either. As I understand it, H.S. does not need a prescription.  The printout stated that it is a drug, but I was told by sellers of the substance that it is not a drug.  Therefore, insurance probably will not cover it ($20 for 100 caps). ANY info would be much appreciated by my mom and I, or any other items on Non-Hodgkins would be good, too.  She’s already had CHOP and fludarabine, and is interested in keeping her partial remission at bay. Thanks for any help, Doris BTW, stop by our WEB homepages Picture Atlas of Arizona and the Southwest & Images of Baja    plus AstroLink  at   http://www.execpc.com/~drogge                       Doris Nerding/Dave Rogge

I think this is about the only doctor who is really pushing it.  I’ve had patients take it, but only get sick on it.  Did her oncologist give her the file on the lack of efficacy of hydrazine from the internet?  H2

Response:

YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE.                   ==HYDRAZINE SULFATE AND CANCERS== 3 AUTHOR                    Filov VA AUTHOR                    Gershanovich ML AUTHOR                    Danova LA AUTHOR                    Ivin BA TITLE                     Experience of the treatment with Sehydrin                           (Hydrazine Sulfate, HS) in the advanced                           cancer patients. SOURCE                    Invest New Drugs; VOL 13, ISS 1, 1995, P89-97 ABSTRACT                  The results of Sehydrin (Hydrazine Sulfate,                           HS) treatment of 740 patients with the                           advanced, recurrent or metastatic solid                           tumours of various localizations or malignant                           lymphomas, for whom all the methods of                           specific treatment (surgery, radiation,                           chemotherapy) had been exhausted are                           presented in this work. The objective                           response, symptomatic therapeutic effects and                           toxicity were estimated. Clinically                           significant objective responses were                           registered in patients with the soft tissue                           sarcomas, including neuroblastomas, and                           paradoxically–in such semimalignant tumours                           as desmoids. Although the objective response                           in patients with the lung cancer                           (90%–non-small cell) was only 4%,                           stabilization of long duration was registered                           in 22% of cases connected with the impressive                           relief of heavy common symptoms in 38.5% of                           the treated patients. Such a subjective                           response was established in 46.6% of all the                           740 cases. The drug given per os was well                           tolerated by patients in primary and                           subsequent courses and did not induce                           myelosuppression or other significant side                           effects. On the basis of observations                           available, Sehydrin may be assessed as an                           alternative drug for the treatment and                           symptomatic therapy of patients with some                           advanced solid tumours and malignant                           lymphomas at a disease stage when the other                           methods of treatment can not be used. A                           possible mechanism of antitumour and                           symptomatic action is being discussed. 4 AUTHOR                    Loprinzi CL AUTHOR                    Goldberg RM AUTHOR                    Su JQ AUTHOR                    Mailliard JA AUTHOR                    Kuross SA AUTHOR                    Maksymiuk AW AUTHOR                    Kugler JW AUTHOR                    Jett JR AUTHOR                    Ghosh C AUTHOR                    Pfeifle DM AUTHOR                    et al TITLE                     Placebo-controlled trial of hydrazine sulfate                           in patients with newly diagnosed                           non-small-cell lung cancer [see comments] SOURCE                    J Clin Oncol; VOL 12, ISS 6, 1994, P1126-9 ABSTRACT                  PURPOSE: Hydrazine sulfate, an agent that                           appears to inhibit gluconeogenesis, has been                           studied in cancer patients for approximately                           20 years. There was a recent resurgence of                           interest in this drug when subset analysis of                           a small placebo-controlled, double-blind,                           clinical trial reported improved survival                           among non-small-cell lung cancer patients                           with a good performance status who were                           randomized to receive this drug along with                           standard chemotherapy. PATIENTS AND METHODS:                           Patients on this trial had newly diagnosed,                           unresectable non-small-cell lung cancer and                           were treated with cisplatin and etoposide. In                           addition, they were randomized to receive                           hydrazine sulfate or placebo in a                           double-blind manner. RESULTS: A total of 243                           patients were randomized. Response rates were                           similar in the two treatment arms. There were                           trends for worse time to progression and                           survival in the hydrazine sulfate arm. No                           significant differences were noted in the two                           study arms with regard to toxicity or quality                           of life (QL). CONCLUSION: This trial failed                           to demonstrate any benefit for patients who                           received hydrazine sulfate. 5 AUTHOR                    Loprinzi CL AUTHOR                    Kuross SA AUTHOR                    O’Fallon JR AUTHOR                    Gesme DH Jr AUTHOR                    Gerstner JB AUTHOR                    Rospond RM AUTHOR                    Cobau CD AUTHOR                    Goldberg RM TITLE                     Randomized placebo-controlled evaluation of                           hydrazine sulfate in patients with advanced                           colorectal cancer [see comments] SOURCE                    J Clin Oncol; VOL 12, ISS 6, 1994, P1121-5 ABSTRACT                  PURPOSE: Hydrazine sulfate is a controversial                           agent that was originally studied in cancer                           patients approximately 20 years ago. Based on                           a series of recent trials that suggested that                           this drug might have utility in cancer                           patients, we conducted this study. PATIENTS                           AND METHODS: Patients with metastatic                           colorectal cancer were randomized to receive                           hydrazine sulfate or placebo in a                           double-blinded manner. Protocol patients did                           not concurrently receive any other systemic                           antineoplastic treatment. RESULTS: There were                           127 assessable patients entered onto this                           clinical trial. Data from the study showed                           trends both for poorer survival and for                           poorer quality of life (QL) in the hydrazine                           group. There were no significant differences                           in the two study arms with regard to anorexia                           or weight loss. CONCLUSION: This trial failed                           to demonstrate any benefit for hydrazine                           sulfate. 10 AUTHOR                    Chlebowski RT AUTHOR                    Bulcavage L AUTHOR                    Grosvenor M AUTHOR                    Oktay E AUTHOR                    Block JB AUTHOR                    Chlebowski JS AUTHOR                    Ali I AUTHOR                    Elashoff R TITLE                     Hydrazine sulfate influence on nutritional                           status and survival in non-small-cell lung                           cancer. SOURCE                    J Clin Oncol; VOL 8, ISS 1, 1990, P9-15 ABSTRACT                  This randomized, prospective,                           placebo-controlled clinical trial compares                           the influence on nutritional status and                           survival of hydrazine sulfate with placebo                           addition to cisplatin-containing combination                           chemotherapy in patients with unresectable                           non-small-cell lung cancer (NSCLC). The trial                           consisted of 65 patients with advanced,                           unresectable NSCLC who had had no prior                           chemotherapy, were at least partially                           ambulatory (Eastern Cooperative Oncology                           Group [ECOG] performance status [PS] level                           0-2), and who had adequate hematologic,                           renal, and hepatic function. All patients                           received the same defined combination                           chemotherapy (cisplatin, vinblastine, and                           bleomycin) and the same defined dietary                           counseling with the addition of either three                           times daily oral hydrazine sulfate (60 mg) or                           placebo capsules. Hydrazine sulfate compared                           with placebo addition to chemotherapy                           resulted in significantly greater caloric                           intake and albumin maintenance (P less than                           .05). Considering all patients, survival was                           greater for the hydrazine sulfate compared                           with placebo group (median survival, 292 v                           187 days), but the difference did not achieve                           statistical significance. In favorable PS                           patients (PS 0-1), survival was significantly                           prolonged (median survival, 328 days v 209                           days; P less than .05) for hydrazine sulfate                           compared with

… read more »

Response:

Dear Dave and Doris, Have you checked out the website at<http://www.sph.uth.tmc.edu/www/utsph/utcam/index.htm ?  It is a site containing all sorts of research materials about ‘alternative’ therapies. Does anyone have any knowledge of, or even possibly, experience with, Hydrazine sulfate in the use of the regression of cancer?

Hydrazine sulfate is an MAO inhibitor.  It’s primary claim is it’s interuption of the cachexia/anorexia symptoms of cancer.  There is no clinical proof that HS, in anyway, acts as a tumorcidal agent. Studies were compiled by the Syracuse Cancer Research Institute/Dr. Joseph Gold on the effectiveness of Hydrazine sulfate in the successful reversal of weight loss and debilitation in some cancer patients. It was also discovered that Hydrazine sulfate regressed or stabilized tumors in some patients also.  The studies that I have read about so far have mentioned primarily brain and lung cancers as far as regression or stabilization of tumors.

Again, check out the above website.  It’s from the U of Texas and contains much info on HS trials and testing.  There’s alot of reading to be done at that site. – Hide quoted text — Show quoted text – One of my questions is:  is this substance something that can be used in lymphomas (my mother has Non-Hodgkins lymphoma)?  She has not had any problems with weight loss so far; on the contrary, she is still overweight and is concerned that this substance, if used, would actually increase her weight – she is mainly looking at Hydrazine sulfate for the tumor regression/stabilization properties. Interferon was suggested to her for the same reasons, but she isn’t too crazy about the idea of this because of the possibly problematic side effects, and the constant trips to the doctor’s office to have it administered. My mother’s oncologist gave us a printout off of the internet about H.S. and tried to contact Dr. Gold by mail, but hasn’t had any luck so far.  I believe this is somewhat new to him, also.  We have tried to contact Dr. Gold by phone, but the receptionist stated that calls are not taken from patients, only medical personnel, so we are having a tough time getting any useful info on this.

If your doctor provided you with a printout, (from which site?), he should also be able to discuss your mothers case with them via phone,  I can provide three phone numbers to the SCRI, where Dr. Gold is the director.  I don’t think I can post them to these NG’s, as I haven’t found out, yet, why one of my posts were removed from the NG alt.support.cancer, dated 3/5/97, but I believe it was because I posted a phone number to the SCRI.  If you will request this info via personal e-mail, I will be happy to supply the phone #’s. Our doctor’s office keeps giving us other numbers, but they are just pharmacy supply places or won’t give out a lot of info over the phone (without $).  So far I haven’t been able to find anything specific to Hydrazine sulfate used with lymphoma on my internet searches either.

Have you tried the NCI at 1-800-4cancer? As I understand it, H.S. does not need a prescription.  The printout stated that it is a drug, but I was told by sellers of the substance that it is not a drug.  Therefore, insurance probably will not cover it ($20 for 100 caps).

This is true, however, I strongly urge you to keep your doctor involved with all treatments, whether they be ‘alternative’ or not.  Do not take the risk of drug reactions on your own.  A doctor should and must be consulted, prior to any change of therapy. ANY info would be much appreciated by my mom and I, or any other items on Non-Hodgkins would be good, too.  She’s already had CHOP and fludarabine, and is interested in keeping her partial remission at bay

My primary research has been with non small cell lung cancer.  I don’t have much info(next to none) on Non-Hodgkins.  However, there are many others in these NG’s with cancer similar to your mothers who will be more than happy to answer questions about Non-Hodgkins. . Thanks for any help,

Your welcome.  Anytime. Sincerely, Larry Hamlin

Response:

Does anyone have any knowledge of, or even possibly, experience with, Hydrazine sulfate in the use of the regression of cancer? Studies were compiled by the Syracuse Cancer Research Institute/Dr. Joseph Gold on the effectiveness of Hydrazine sulfate in the successful reversal of weight loss and debilitation in some cancer patients. It was also discovered that Hydrazine sulfate regressed or stabilized tumors in some patients also.  The studies that I have read about so far have mentioned primarily brain and lung cancers as far as regression or stabilization of tumors. One of my questions is:  is this substance something that can be used in lymphomas (my mother has Non-Hodgkins lymphoma)?  She has not had any problems with weight loss so far; on the contrary, she is still overweight and is concerned that this substance, if used, would actually increase her weight – she is mainly looking at Hydrazine sulfate for the tumor regression/stabilization properties. Interferon was suggested to her for the same reasons, but she isn’t too crazy about the idea of this because of the possibly problematic side effects, and the constant trips to the doctor’s office to have it administered. My mother’s oncologist gave us a printout off of the internet about H.S. and tried to contact Dr. Gold by mail, but hasn’t had any luck so far.  I believe this is somewhat new to him, also.  We have tried to contact Dr. Gold by phone, but the receptionist stated that calls are not taken from patients, only medical personnel, so we are having a tough time getting any useful info on this.  Our doctor’s office keeps giving us other numbers, but they are just pharmacy supply places or won’t give out a lot of info over the phone (without $).  So far I haven’t been able to find anything specific to Hydrazine sulfate used with lymphoma on my internet searches either. As I understand it, H.S. does not need a prescription.  The printout stated that it is a drug, but I was told by sellers of the substance that it is not a drug.  Therefore, insurance probably will not cover it ($20 for 100 caps). ANY info would be much appreciated by my mom and I, or any other items on Non-Hodgkins would be good, too.  She’s already had CHOP and fludarabine, and is interested in keeping her partial remission at bay. Thanks for any help, Doris BTW, stop by our WEB homepages  Picture Atlas of Arizona and the Southwest & Images of Baja     plus AstroLink  at   http://www.execpc.com/~drogge                        Doris Nerding/Dave Rogge

Response:

Related Posts

No comments yet.

Leave a Comment